Allogene Stock Jumps As Off‑The‑Shelf CAR‑T Wipes Out Residual Lymphoma In Early Readout
Allogene Therapeutics (NASDAQ: ALLO) is up more than 50%, trading sharply higher after early data showed its off‑the‑shelf CAR‑T candidate cema‑cel eliminated lingering lymphoma cells far more effectively than standard care in B‑cell lymphoma patients who had finished first‑line chemo but still had minimal residual disease (MRD). In an initial 24‑patient cut from the randomized ALPHA3 trial, 58% of patients on cema‑cel achieved MRD‑negative status versus only 16% on observation alone, clearing the trial’s interim bar for a clinically meaningful benefit and suggesting the therapy may meaningfully reduce relapse risk.
Beyond MRD, cema‑cel drove a roughly 98% average reduction in circulating lymphoma DNA by day 45, compared to a 27% increase in the control arm, and did so without any reported cases of cytokine release syndrome or ICANS, the serious immune toxicities often seen with autologous CAR‑Ts. Ten of twelve cema‑cel patients were managed entirely in the outpatient setting, reinforcing Allogene’s pitch that an off‑the‑shelf product manufactured from donor cells could ultimately be given at “biologic‑like” scale rather than limited to specialized transplant centers.
For ALLO investors, this is an important de‑risking step rather than the finish line: the key question is whether early MRD clearance translates into better event‑free survival and fewer relapses over time. ALPHA3 remains blinded and is expected to complete enrollment around 2027, with pivotal EFS data slated for mid‑2027 and mid‑2028; backed by a cash runway into 2028, Allogene is positioning cema‑cel to become the first donor‑derived CAR‑T approved for lymphoma if those outcomes hold up.
